Quest Diagnostics Incorporated DGX
236.32
(0.27)
(0.11%)
as of 25 Sep
- Market cap
- $26.2B
- P/E
- 24.8×
Follow DGX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Quest Diagnostics Incorporated (DGX) P/E ratio
As of 25 September 2026, Quest Diagnostics Incorporated (DGX) trades at a P/E ratio of 24.8×. Over the past ten years it has ranged from 7.7× (June 2021) to 25.9× (September 2026); the current reading is higher than 99% of that period. That is below the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 19.6× | 0.89% |
| FY2024 | 19.4× | 4.51% |
| FY2023 | 18.6× | (4.00%) |
| FY2022 | 19.3× | 77.28% |
| FY2021 | 10.9× | (3.03%) |
| FY2020 | 11.2× | (33.04%) |
| FY2019 | 16.8× | 8.69% |
| FY2018 | 15.4× | (12.05%) |
| FY2017 | 17.6× | (13.16%) |
| FY2016 | 20.2× | 39.91% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 22.2× | 3.95% |
| Mar 2026 | 21.4× | 9.24% |
| Dec 2025 | 19.6× | (11.31%) |
| Sep 2025 | 22.1× | 4.01% |
| 42 more quarters | Free account |
Against its own ten years
Low 7.7×
High 25.9×
Ten-year median
18.5×
Current reading's percentile
99
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated | 24.8× |
| LH Labcorp Holdings Inc. compare | 25.4× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| MEDP Medpace Holdings, Inc. compare | 35.6× |
| IDXX IDEXX Laboratories, Inc. compare | 36.2× |
| ILMN Illumina, Inc. compare | 50.4× |
| RVTY Revvity Inc. compare | 72.0× |
| WAT Waters Corporation compare | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on DGX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement